Hypertension after renal transplantation

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 101-109

  Dikow, R ^a   Zeier, M ^a   Ritz, E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Calcineurin, inhibitors; Graft rejection; Hypertension; Kidney transplantation; Polycythemia; Renal artery obstruction

Indexed keywords

CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; VASOCONSTRICTOR AGENT;

BLOOD PRESSURE REGULATION; GENETIC PREDISPOSITION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; POLYCYTHEMIA; PREVALENCE; RECIPIENT; REVIEW; SODIUM RETENTION;

ANTIHYPERTENSIVE AGENTS; GRAFT SURVIVAL; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; PREVALENCE; SURVIVAL RATE;

EID: 0038110722     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Van Ypersele de Strihou C, Vereerstaeten P, Wauthier M, Toussaint Ch, Pirson Y, dePlaen JF et al. Prévalence, étiologie et traitement de l'hypertension après transplantation rénale. In: Grünfeld JP, editor. Actualités Néphrologiques de l'Hôpital Necker. Paris: Flammarion; 1982.p.43-59.
2. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;2:151-83.
3. Ritz E, Schwenger V, Zeier M. Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 2001;16:1550-4.
4. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van BCT. Complications of cyclopsorine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987;43:197-204.
5. Jarowenko MV, Flechner SM, Van BCT, Lorber MI, Kahan BD. Influence of cyclosporine on posttransplant blood pressure response. Am J Kidney Dis 1987;10: 98-103.
6. Ferro CJ, Savage T, Pinder SJ, Tomson CR. Central aortic pressure augmentation in stable renal transplant recipients. Kidney Int 2002;62:166-71.
7. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000;283:633-8.
8. Guyton AC. Blood pressure control: special role of the kidneys and body fluids. Science 1991;252:1813-6.
9. Clemitson JR, Pratt JR, Frantz S, Sacks S, Samani NJ. Kidney specificity of rat chromosome 1 blood pressure quantitative trait locus region. Hypertension 2002;40:292-7.
10. Churchill PC, Churchill MC, Bidani AK, Kurtz TW. Kidney-specific chromosome transfer in genetic hypertension: the Dahl hypothesis revisited. Kidney Int 2001;60:705-14.
11. Grisk O, Rose HJ, Lorenz G, Rettig R. Sympathetic-renal interaction in chronic arterial pressure control. Am J Physiol Regul Integr Comp Physiol 2002;283: R441-50.
12. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983;309: 1009-14.
13. Basset el EA, Berthoux P, Cecillon S, Deprle C, Thibaudin D, De Fillipis JP et al. Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 and ecNOS. Clin Nephrol 2002;57:192-200.
14. Abdi R, Tran TB, Zee R, Brenner BM, Milford EL. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 2001;72:726-9.
15. Beige J, Kreutz R, Tscherkaschina I, Scherer S, Sharma AM, Zidek W et al. Matrix analysis for the dissection of interactions of G-protein beta3 subinut C825T genotype, allograft function, and posttransplant hypertension in kidney transplantation. Am J Kidney Dis 2002;40:1319-24.
16. Frei U, Schindler R, Wieters D, Grouven U, Brunkhorst R, Koch KM. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995;10:1206-11.
17. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure; less of one, more the other? Am J Hypertens 1988;1:335-47.
18. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
19. Perico N, Ruggenenti P, Scalamogna M, Locatelli G, Remuzzi G. One or two marginal organs for kidney transplantation? Transplant Proc 2002;34:3091-6.
20. Remuzzi G. Double transplant of marginal kidneys. Transplant Proc 1999;31:2962-4.
21. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996;50:1321-6.
22. Curtis JJ, Luke JG, Jones P, Dietheim AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium-dependent. Am J Med 1988;85:134-8.
23. Cheigh JS, Haschemeyer RH, Wang JCL, Riggio RR, Tapia L, Stenzel KH et al. Hypertension in kidney transplant recipients. Effect on longterm renal allograft survival. Am J Hypertens 1989;2:341-8.
24. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998;13:3091-5.
25. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-22.
26. Floege J, Burg M, Kliem V. Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant 1998;13:1933-5.
27. Briggs J, Jones E. Recurrence of glomerulonephritis following renal transplantation. Nephrol Dial Transplant. 1999;14:564-5.
28. Carter JT, Lee CM, Weinstein RJ, Lu AD, Dafoe DC, Alfrey EJ. Evaluation of the older cadaveric kidney donor: the impact of donor hypertension and creatinine clearance on graft performance and survival. Transplantation 2000;70:765-71.
29. Farge D, Julien J, Kreft C, Guyenne TT, Boilaud O, Plouin PF et al. Renin stimulation after cardiac and liver transplantation in cyclosporine-treated hypertensive recipients. J Hypertens Suppl 1991;90:199A.
30. Thomson ME, Shapiro AP, Johnson AM. The contrasting effects of cyclosporine A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. Int J Cardiol 1986;11:985-95.
31. Kone BC. Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med 1988;69:985-95.
32. Deray G, Behnmida M, Le Hoang P. Renal function and blood pressure in patients receiving long-term low-dose cyclosporine therapy for idiopathic uveitis. Ann Intern Med 1992;117:578-83.
33. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001;72:S9-12.
34. First RM, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994;4:S30.
35. Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep 2001;3:434-9.
36. Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ et al. Pronoucend renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporine A versus FK 506. Transplant Int 1998;11:3-10.
37. Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS. The sodium retaining effects of cyclosporine. Kidney Int 1992;41:1599-605.
38. Wolf G, Killen PD, Nielson EG, Cyclosporine A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J Am Soc Nephrol 1990;1:918-22.
39. Kurtz A, Delia BR, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988;33:947-53.
40. Mason J, Muller-Schweinitzer E, Dupont M, Casellas D, Mihatsch M, Moore L et al. Cyclosporine and the renin-angiotensin system. Kidney Int 1991;39:S28-32.
41. Haass M, Mayer G. Cyclosporine A associated hypertension: pathomechanisms and clinical consequences. Nephrol Dial Transplant 1996;12:395-8.
42. Rego A, Vargas R, Wroblewska B, Foegh ML, Ramwell PW. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporine A. J Pharmacol Exp Ther 1990;252:165-70.
43. Perico N, Benigni A, Zoja C, Delaini F, Remuzzi G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol 1986;251:F581-7.
44. Reis F, Tavares P, Fontes Ribeiro CA, Antunes F, Texeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb Res 1999;96:365-72.
45. Scherrer U, Vissing SF, Morgan BJ. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:633-9.
46. Zhang W, Li JL, Hosaka M, Janz R, Shelton JM, Albnight GM et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. PNAS 2000;98:9765-70.
47. Jensik SC, and the FK506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 1998;30: 1216.
48. Margreiter R, and the European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group. A prospective, randomized, multicentre study to compare the efficiacy and safety of tacrolimus and ciclosporin-microemulsion in renal transplantation. Transplantation 2000;69:S112.
49. Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1999;31:S64.
50. Ligtenberg G, Hene RJ, Blankstijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant recipients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001;12:368.
51. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86.
52. Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus and cyclosporine. Transplantation 1996;62: 1588-92.
53. Coffman TM, Himmelstein S, Best C, Klotman PE. Posttransplant hypertension in the rat: effects of captopril and native nephrectomy. Kidney Int 1989;36:35-40.
54. Teixeira MC, Nahas WC, Mazucchi E, Ianhez LE, David-Neto E. Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-transplanted patients. Nephrol Dial Transplant 1998;13:2092-7.
55. Yasumara T, Oka T, Aikawa Y, Ohmon Y, Nakane Y. Beneficial effect of bilateral nephrectomy on long-term survival of living related kidney allografts. Transplant Proc 1989;21:1967-9.
56. Curtis JJ, Lucas BA, Kotchen TA, Luke RG. Surgical therapy for persisting hypertension after renal transplantation. Transplantation 1981;31:125-8.
57. Recordati G, Zorzoli F, Zanchetti A. Effects of a reversible nephrectomy on renal sympathetic activity and blood pressure in the rat: evidence for an acute angiotensin-mediated hypertension. J Hypertens 2000;18: 1277-87.
58. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-9.
59. Lye WC, Leong SO, Lee EJ. Transplant renal artery stenosis presenting with recurrent acute pulmonary edema. Nephron 1996;72:302-4.
60. Felten H, Kuhn K. Renovascular hypertension after renal transplantation. Don't look only after the graft artery. Nephrol Dial Transplant 1996;11:1383-4.
61. Campieri C, Gregorini MR, Moschella MR, Pema C, Rossi C, Stefoni S et al. Fibromuscular dysplasia in a transplanted kidney. Nephrol Dial Transplant 1998;13: 1299.
62. Japichino GG, Bonati L, Rubini P, Capocasale E. Prevalence of atherosclerosis in renal transplant recipients. Minerva Cardioangiol 2001;49:229-38.
63. Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, Sirin A. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 2001;16:2041-7.
64. Aeberhard JM, Schneider PA, Valloton MB, Kurtz A, Leski M. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 1990;50:613-6.
65. Ducloux D, Motte G, Kribs M, Abdelfatah AB, Bresson-Vautrin C, Rebibou JM et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002;57:409-13.
66. Haribaran S, Johnson CP, Bresnahan BA, Taronto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
67. Schwenger V, Zeier M, Wiesel M, Ritz E. Cardiovascular complications after renal transplantation. In: Cochat P, Traeger J, Merieux C, Derchavane M, editors. Immunosuppression under trial. Boston: Kluwer Academic Publishers; 1999.p.81-8.
68. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000;36:S24-30.
69. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
70. Amenabar JJ, Garcia-Lopez F, Robles MR, Saracho R, Calero M, Gentil MA et al. 1997 Spanish nephrology association (Sociedad Espanola de Nefrologia) report on dialysis and transplantation. Nephrol Dial Transplant 1999;14:2841-5.
71. McGregor E, Jardine A, Murray L, Dargie H, Rodger R, Junor B et al. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant 1998;13:1499-505.
72. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001;72:107-11.
73. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158-65.
74. Cosio FG, Dillon JJ, Falkenhain ME, Tesi RJ, Henry ML, Elkhammas EA et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995;47:1136-41.
75. Schindler R, Tanriver Y, Frei U. Hypertension and allograft nephropathy: cause, consequence, or both? Nephrol Dial Transplant 2000;15:8-10.
76. Kusaka M, Mackenzie HS, Ziai F, Hancock WW, Tilney NL. Recipient hypertension potentiates chronic functional and structural injury of rat renal allografts. Transplantation 2002;74:307-14.
77. Paul LC. Gomerular hypertension: an under-appreciated aspect of chronic rejection. Nephrol Dial Transplant 2001;16:213-5.
78. Cosio FG, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM, Mitchell L et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001;59:1158-64.
79. Van der Schaaf MR, Hene RJ, Floor M, Blanckestijn PJ, Koomans HA. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995;25:77.
80. Kew CE II, Curtis JJ. Hypertension after renal transplantation. Graft 2000;3:172.
81. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appell LJ, Charleston J et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK-trial. JAMA 2002;288:2421-31.
82. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J Am Soc Nephrol 2001;12:2832-7.
83. Asberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function on long-term treatment with lisinopril than nifedipine in renal transplant recipients. Nephrol Dial Transplant 2001;16:1465-70.
84. Matteucci E, Carmellini M, Bertoni C, Boldrini E, Mosca F, Giampietro O. Urinary excretion rates of multiple renal indicators after kidney transplantation: clinical sgnificance for early graft outcome. Ren Fail 1998;20: 325-30.
85. Martinez-Ocana JC, Bonet J, Castellote E, Lauzurica R, Caralps A. Microalbuminuria as a marker of kidney dysfunction in renal transplant patients. Transplant Proc 1995;27:2233-4.
86. Roodnat JI, Mulder PG, Rischen-Vos J, van Riemsdijk IC, van Gelde T, Zietse R et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001;72:438-44.
87. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999;33:862-8.
88. Powell JS, Muller RK, Baumgartner HR. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1991;17:137B-42.
89. Michel JB, Plissonnier D, Bruneval P. Effect of perindopril on the immune arterial wall remodelling in the rat model of arterial graft rejection. Am J Med 1992;92: S39-46.
90. Schwenger V, Zeier M, Ritz E. Arterielle Hypertonie nach Nierentransplantation. Spektrum Nephrol 2000;5: 3-14.
91. Prasad GV, Ahmed N, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003;63: 360-4.
92. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.
93. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: 851-60.
94. Lewington S, Clarke R, Oizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.